ANGPT1: Angiopoietin-1
Binds and activates TEK/TIE2 receptor by inducing its dimerization and tyrosine phosphorylation.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ANGPT1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Other 2
| Trebananib | Phase 3 | Amgen | Other | InhibitorAngiopoietin-1 inhibitor | 1 |
| AMG-780 | Phase 1 | Amgen | Other | InhibitorAngiopoietin-1 inhibitor | 0 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Trebananib | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | Jan 5, 2010 |
- Open-angle glaucoma0.53
- Glaucoma0.51
- Hereditary angioedema0.39
- Varicose veins0.37
- Ovarian carcinoma0.36
- Malignant epithelial tumor of ovary0.36
- Primary peritoneal carcinoma0.36
- Fallopian tube cancer0.36
- Cervical carcinoma0.35
- Alcohol drinking0.34
- Vein disorder0.34
- Lymphatic system disorder0.34
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3217395, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q15389, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets